Overview
This is a prospective, single-center, single arm, open label study to evaluate the performance of 68Ga-FAPI-46 for the diagnosis of primary and metastatic lesions of lung cancer with comparison to 18F-FDG PET.
Description
FDG-PET imaging is recommended by clinical guidelines for staging of lung cancer; however, there are still limitations of FDG-PET in lung cancer staging due to false-positive and false-negative findings. 68Ga-FAPI PET images have shown high diagnostic performance with high tumor-to-background ratio in various cancers. The purpose of this study is head-to-head comparison of 68Ga-FAPI-46 PET and 18F-FDG PET for the diagnosis and staging or re-staging of lung cancer.
Eligibility
Inclusion Criteria:
- Age > 20 years
- Informed consent obtained from patients and families
- Patients with histology confirmed lung cancer or patients with GGO on chest CT planned to have biopsy or surgery
- Patients scheduled to undergo FDG-PET examination
- Performance status: 0, 1, 2, 3
Exclusion Criteria:
- Contraindication to FAPI-PET and FDG-PET such as pregnant, or lactating patients
- Patients with mainly malignant pleural effusion without other measurable lesions
- Undergoing irradiation at accrual
- Active infection or other serious underlying medical conditions not compatible with study entry
- History of significant neurological or psychiatric disorders including dementia that would prohibit the understanding and giving of informed consent